In brief
Researchers reveal this innovative tablet combines two anti-parasitic drugs, offering a promising solution to a widespread health problem affecting about 1.5 billion people.
A new mango-flavored pill could revolutionize the treatment of intestinal worms, presenting a promising alternative in the fight against parasitic infections that impact approximately 1.5 billion individuals worldwide. This tablet, currently in development, merges two existing anti-parasitic drugs, yielding better results in trials and potentially addressing the challenges of drug resistance.Intestinal worms, particularly soil-transmitted helminths like whipworm and hookworm, primarily infiltrate humans through contaminated food and water, leading to malnutrition, anemia, and severe gastrointestinal issues. These parasites are especially prevalent in developing nations with poor hygiene practices, affecting numerous children.The research initiative, known as "ALIVE," detailed in a recent Lancet publication, highlights the pill's potential to support countries in achieving World Health Organization targets aimed at eradicating the diseases. The dosing regimen consists of either a single tablet or a trio of pills over consecutive days, significantly simplifying treatment administration.Project leader Prof. Jose Muñoz emphasized the pill's ease of use and its strategy to mitigate drug resistance by combining medications with different action mechanisms. This dual-drug approach is critical as a growing number of intestinal parasites are becoming resistant to existing treatments.Clinical trials conducted in Ethiopia, Kenya, and Mozambique with 1,001 children aged 5-18 demonstrated that the combination of the drug albendazole and ivermectin proved effective against various parasitic infections. However, researchers noted limitations in how well it addressed threadworm infections.Prof. Hany Elsheikha, a parasitology expert from the University of Nottingham, termed this pill a "significant improvement" over current treatments, asserting its capability against multiple parasites. Nevertheless, he pointed out that while the preliminary findings are promising, they leave several unanswered questions regarding diverse age groups and global applicability.The trial results have been submitted to European and African regulators, with decisions anticipated by early 2025. A broader trial involving 20,000 participants is set to commence in Kenya and Ghana, spearheaded by Dr. Stella Kepha from the Kenya Medical Research Institute. She highlighted the pill's potential to enhance the health of affected communities, stressing the need for further work before widespread implementation.
